SAN FRANCISCO, Jan. 9, 2017 /PRNewswire/ -- ResMed
(NYSE:RMD) announced today at the 35th annual J.P.
Morgan Healthcare Conference that the U.S. Food and Drug
Administration has cleared ResMed's AirMini, the world's smallest
continuous positive airway pressure (CPAP) device.
ResMed's tiny yet fully-featured AirMini, to be launched later
this year, is designed as a secondary CPAP, making it easier for
people to continue their sleep apnea therapy while traveling.
As an addition to ResMed's industry-leading Air Solutions
portfolio, the AirMini offers multiple benefits to home medical
equipment providers—supporting increased therapy compliance and
convenience for their patients, and incremental revenue
opportunities.
"ResMed AirMini is the portable travel CPAP patients and home
medical equipment providers have been waiting for, and we look
forward to bringing it to market later this year," said ResMed CEO,
Mick Farrell. "It fits easily in
carry-on luggage – even in the seatback pocket on the plane–and
delivers all the best-in-class comfort features patients need to
get the best sleep."
About ResMed
ResMed (NYSE:RMD) changes lives with
award-winning medical devices and cutting-edge cloud-based software
applications that better diagnose, treat and manage sleep apnea,
chronic obstructive pulmonary disease (COPD) and other chronic
diseases. ResMed is a global leader in connected care, with more
than 2 million patients remotely monitored every day. Our
5,000-strong team is committed to creating the world's best
tech-driven medical device company – improving quality of life,
reducing the impact of chronic disease, and saving healthcare costs
in more than 100 countries.
ResMed.com | Facebook | Twitter | LinkedIn
For
media:
|
For
investors:
|
Alison
Graves
|
Agnes Lee
|
O:
858-836-6789
|
O:
858-836-5971
|
news@resmed.com
|
investorrelations@resmed.com
|
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/fda-clears-worlds-smallest-cpap-resmed-airmini-300387554.html
SOURCE ResMed Inc.